All News
Antibiotics are not linked to Autoimmune disease in kids
d
EurekAlert!
The global incidence of autoimmune diseases among children has increased over the past few decades.
Read Article
Sjögren's Graduates (8.22.2025)
Dr. Jack Cush reviews the news, journal reports, FDA approvals, drug safety, and more from this week.
Read Article
It's now called Sjögren Disease!
Sjögren syndrome is now Sjögren disease, according to recommendations stemming from the 2023 International Rome consensus for the nomenclature of Sjögren disease.
Read Article
Cardiovascular Sequelae in Adults After Kawasaki Disease
A long-term cohort study of children diagnosed with Kawasaki disease (KD) shows evidence of future adult cardiovascular complications and hospitalizations. These severe cardiovascular events clustered during the young KD adults and later, a second surge in their late 30s.
Read Article
Safety of Combination Targeted Therapies in Psoriatic Arthritis
d
MedPage Today
Treating psoriatic arthritis (PsA) patients with more than one targeted therapy appears to be just fine, with no increased risk of serious infections, insurance claims data indicate.
Read Article
Rheums Speak: Future of Rheumatoid Arthritis
The third survey in this series addressed clinician views on future trends (AI), future therapies and lessons learned.
Read Article
FDA has granted Soligenix "Orphan Drug Designation" to study dusquetide in the treatment of Behçet's dz, based on an 8 patient proof of concept Phase 2a trial. Not yet FDA approved, dusquetide is a short peptide innate defense regulator (IDR). Behcets affects 18K in USA and https://t.co/RzzVuQ6bAB
Dr. John Cush RheumNow ( View Tweet)
Single-center Retrospective study of 4,736 RA, propensity matched 509 w/ RA-ILD vs 509 without ILD. In multivariate analysis RF positivity was an independent risk factor for RA-ILD (adj OR = 1.5) w/ signif nonlinear relationship observed, risk threshold @60 IU/mL Paradoxical https://t.co/0XtWnIsbmK
Dr. John Cush RheumNow ( View Tweet)
Telitacicept, a BLyS (BAFF)/APRIL dual-target fusion drug, announced it has met the primary endpoint in its Phase III clinical trial in treating primary Sjögren's syndrome (pSS) in China. Primary endpoint was the change in ESSDAI score at Week 24. https://t.co/afOgpGLdV1 https://t.co/9EKbbrCgTL
Dr. John Cush RheumNow ( View Tweet)
Gout Education Card for Patients - Info & Rules #1
https://t.co/uppST8OBLZ https://t.co/3Ry3erNJCL
Dr. John Cush RheumNow ( View Tweet)
Gout Education Card for Patients - Diagnosis & Management #2 https://t.co/uppST8OBLZ https://t.co/sLF5WPeuA5
Dr. John Cush RheumNow ( View Tweet)
TriNetX database study shows Beta blocker use assoc w/ more hip replacements (THA). 23K propensity matched pts (mean age 69) on or off BB compared. After 3 yrs BB use was assoc w/ higher risk of THA (HR 1.49; 1.4–1.59), esp w/ alpha-BBs (HR 1.64) https://t.co/W6ocMYI653 https://t.co/EiQ4WH94cD
Links:
Dr. John Cush RheumNow ( View Tweet)
New IDSA recommendation: In hospitalized on systemic steroids w/ severe, critical, progressing COVID-19, when baricitinib or tocilizumab are not available, IDSA guideline panel suggests infliximab. https://t.co/ZCkkZXUDpi https://t.co/gbgkvj5R8Y
Dr. John Cush RheumNow ( View Tweet)
ChildCAPTURE & BioCAPTURE registry studies of 117 pediatric & 243 young adult Psoriasis pts on biologics (753.4 Pt-Yrs) shows no sex differences in clinical responses, but shows females have more adverse events than males (both cohorts) https://t.co/5at9vCqwIO https://t.co/ScJkIH9G31
Links:
Dr. John Cush RheumNow ( View Tweet)
Uncertainty with immunosuppressive for idiopathic inflammatory myopathies
A current Cochrane review suggests a continued unmet need regarding the status and utility of targeted immunosuppressant and immunomodulatory treatments for IIM.
https://t.co/evkwbX6U9j https://t.co/2s0Z9Y9Umm
Dr. John Cush RheumNow ( View Tweet)
Claims data study of 82 399 PsA pts - 542 on combo targeted Rx >3 mos (200 > 6mos). 2 most common combos of apremilast w/ TNFi or IL-17i. Use of combo targeted Tx was not assoc. w/ more serious infxn (RRs 0.53; 0.17-1.63) or opportunistic infx (RR 1.00; 0.09-11.02) @ 3 or 6 mos https://t.co/mkvq1lqt9Y
Dr. John Cush RheumNow ( View Tweet)
RCT of 2331 chronic MSK pain pts showed that telehealth Cognitive behavioral therapy (CBT) (health coach) superior to self-care (Pain trainer) or usual care at achieving a >30% reduction in pain (32% vs 26.6% vs 20.8% respectively) & benefits were sustained at 12 months. https://t.co/a69zPsJslH
Dr. John Cush RheumNow ( View Tweet)
The global autoimmune disease treatment market was valued at $7 billion USD in 2024 and is expected to rise to ~$11 billion by 2030 and reach $12.6 billion by 2032 https://t.co/C5IQ0hUvQE https://t.co/RjbMo5cCOl
Dr. John Cush RheumNow ( View Tweet)
Clinical Rheumatology Thread for Busy GPs:
Post 1
Early inflammatory arthritis(IA): the 3–3–3 rule
•Onset ≤3 months
•Morning stiffness ≥30–60 minutes
•≥3 swollen joints (MCP/MTP common)
If present, manage as IA: urgent rheum referral; NSAIDs if no contraindications. https://t.co/hcoumX1ZVY
Aravind Palraj Rheumat_Aravind ( View Tweet)
TNF Inhibitors in Takayasu's Arteritis
A large, retrospective, multicenter study demonstrated the efficacy of intravenous infliximab and subcutaneous adalimumab in patients with Takayasu arteritis.
https://t.co/lJbvaYnylO https://t.co/uRBruhW2Fd
Dr. John Cush RheumNow ( View Tweet)
